Off-label use of recombinant factor Vlla: why we need better drug monitoring

Hébert, Paul C.; Fergusson, Dean; Stanbrook, Matthew B.
January 2011
CMAJ: Canadian Medical Association Journal;1/11/2011, Vol. 183 Issue 1, p26
Academic Journal
In this article the author discusses the importance of drug monitoring regarding the off-label use of recombitant factor VIIa. According to the author, VIIa was first licensed in 1996 for the treatment and prevention of bleeding connected to surgery for people with hemophilia. He adds that drug monitoring can be done by having a better collaboration between the payer and the insurer and having health professionals participate in evidence-based evaluation of new drugs.


Related Articles

  • Haemophilia part 1 : an introduction. Khalr, Kate // British Journal of Nursing;6/13/2013, Vol. 22 Issue 11, p620 

    The author discusses haemophilia, with a focus on the disease's incidence, genetic transmission, and symptoms including severe bleeding manifestations. Topics include X-linked disorders and haemophilia A, diagnosis by blood clotting screen and factor assay, and activated partial thromboplastin...

  • Lifesaving Stopgap for Bleeders.  // Time;8/6/1965, Vol. 86 Issue 6, p66 

    The article reports on the method discovered by Stanford University physiologist Judith Graham Pool that aims to prevent hemorrhages by concentrating clot-promoting proteins for hemophilia victims. Pool reveals that frozen plasma leaves the antihemophilic globulin (AHG), which is insufficient in...

  • New hemophilia treatment approved. Key, Nigel // Hem/Onc Today;3/10/2008, Vol. 9 Issue 4, p9 

    The article reports on the U.S. Food & Drug Administration approval of Wyeth Pharmaceuticals' Xyntha, a recombinant factor VIII for the treatment of hemophilia A for the control and prevention of bleeding episodes and surgical prophylaxis. It was genetically engineered from the genes of Chinese...

  • Assessment of community pharmacists concerning pharmacovigilance in Iraq. Salih, Muhannad R. M.; Abd, Arwa Y.; Kurmanji, Jaafer M.; Al-Lela, Omer Qutaiba B. // Archives of Pharmacy Practice;Oct-Dec2016, Vol. 7 Issue 4, p136 

    Objectives: This study was designed to explore the awareness and attitude of the pharmacists working in the retail pharmacies toward the national adverse drug reactions (ADRs) system activities in Iraq. Methods: A cross-sectional survey using a validated self-administered questionnaire was used...

  • Letter to the Editor. Brooks, Judith B.; Boone, Donna C.; Frelick, Robert W. // American Journal of Public Health;Aug1976, Vol. 66 Issue 8, p795 

    Several letters to the editor are presented related to health care including "Survey of Nurse-Midwives to be Conducted," by Judith Brooks, "Trend Toward Longevity in Hemophiliacs," by Donna C. Boone and "Coming to Grips with the Main Issue" by Robert W. Frelick.

  • Managing hemophilia: the role of mobile technology. Khair, Kate; Holland, Mike // Smart Homecare Technology & TeleHealth;2014, Vol. 2, p39 

    The ubiquity of mobile technology offers the potential for instantaneous and two-way transfer of information, as well as the potential for improving medical care delivery and extending it to those in countries and regions with a less developed medical infrastructure. This review considers the...

  • Role of argatroban during neurointerventional procedures in patients with heparin induced thrombocytopenia. Alaraj, Ali; Tobin, Matthew; Birk, Daniel; Aletich, Victor // Journal of NeuroInterventional Surgery;Oct2014, Vol. 6 Issue 8, p630 

    Background Currently, heparin is used routinely for anticoagulation during cerebral angiography and neurointerventional procedures. In patients with heparin sensitivity, however, heparin cannot be used. Therefore, an alternative method of anticoagulation is necessary to prevent clot formation...

  • Rate and Extent of Drug Accumulation after Multiple Dosing Revisited. Brocks, Dion R.; Mehvar, Reza // Clinical Pharmacokinetics;2010, Vol. 49 Issue 7, p421 

    For drugs that have a narrow therapeutic margin in their concentration-effect profile, blood concentration measurements can be an invaluable guide to the individualization of dosage regimens. For clinicians involved in therapeutic drug monitoring, background knowledge of basic pharmacokinetics...

  • Physician reporting of adverse drug reactions. Results of the Rhode Island Adverse Drug Reaction Reporting Project. Scott, H. Denman; Thacher-Renshaw, Ann; Rosenbaum, Sara E.; Waters Jr., William J.; Green, Marilyn; Andrews, Lisa G.; Faich, Gerald A.; Scott, H D; Thacher-Renshaw, A; Rosenbaum, S E; Waters, W J Jr; Green, M; Andrews, L G; Faich, G A // JAMA: Journal of the American Medical Association;4/4/90, Vol. 263 Issue 13, p1785 

    The Food and Drug Administration, Rockville, Md, contracted with the Rhode Island Department of Health, Providence, to conduct a project to increase reporting of suspected adverse drug reactions through physician education. Voluntary reporting, an important part of postmarketing surveillance...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics